OVID THERAPEUTICS INC (OVID)
US6904691010 - Common Stock
Overall OVID gets a fundamental rating of 3 out of 10. We evaluated OVID against 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for OVID as it has an excellent financial health rating, but there are worries on the profitability. OVID has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year OVID has reported negative net income.
OVID had a negative operating cash flow in the past year.
OVID had negative earnings in 4 of the past 5 years.
OVID had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
OVID has a Return On Assets of -36.40%. This is in the better half of the industry: OVID outperforms 64.44% of its industry peers.
With a decent Return On Equity value of -59.71%, OVID is doing good in the industry, outperforming 61.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.4% | ||
| ROE | -59.71% | ||
| ROIC | N/A |
ROA(3y)-3.22%
ROA(5y)-38.25%
ROE(3y)-11.3%
ROE(5y)-61.22%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for OVID so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OVID does not have a ROIC to compare to the WACC, probably because it is not profitable.
OVID has more shares outstanding than it did 1 year ago.
OVID has more shares outstanding than it did 5 years ago.
OVID has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -0.89, we must say that OVID is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of OVID (-0.89) is comparable to the rest of the industry.
There is no outstanding debt for OVID. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.89 |
ROIC/WACCN/A
WACC9.23%
2.3 Liquidity
A Current Ratio of 9.55 indicates that OVID has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.55, OVID is in the better half of the industry, outperforming 79.32% of the companies in the same industry.
A Quick Ratio of 9.55 indicates that OVID has no problem at all paying its short term obligations.
OVID has a better Quick ratio (9.55) than 79.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.55 | ||
| Quick Ratio | 9.55 |
3. Growth
3.1 Past
OVID shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.60%.
The Revenue for OVID has decreased by -68.46% in the past year. This is quite bad
OVID shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -68.56% yearly.
EPS 1Y (TTM)2.6%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-37.5%
Revenue 1Y (TTM)-68.46%
Revenue growth 3Y-68.56%
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to decrease by -4.02% on average over the next years.
OVID is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 233.99% yearly.
EPS Next Y-13.97%
EPS Next 2Y27.19%
EPS Next 3Y-4.02%
EPS Next 5YN/A
Revenue Next Year-26.7%
Revenue Next 2Y1096.53%
Revenue Next 3Y357.96%
Revenue Next 5Y233.99%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
OVID reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OVID. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as OVID's earnings are expected to decrease with -4.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.19%
EPS Next 3Y-4.02%
5. Dividend
5.1 Amount
No dividends for OVID!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OVID THERAPEUTICS INC
NASDAQ:OVID (4/18/2024, 7:12:42 PM)
After market: 3.21 0 (0%)3.21
+0.1 (+3.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap226.98M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.4% | ||
| ROE | -59.71% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.55 | ||
| Quick Ratio | 9.55 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)2.6%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-13.97%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-68.46%
Revenue growth 3Y-68.56%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y